Porównanie niepożądanych reakcji w krwi u pacjentów z epilepsją leczonych jednym lekiem versus wieloma lekami

PubMed➕ 22.04.2026Int J Risk Saf Med

Comparison of hematological adverse reactions in patients with epilepsy on monotherapy versus polytherapy

W skrócie

Badanie porównało wpływ leczenia epilepsji jednym lekiem i wieloma lekami na parametry krwi u pacjentów. Okazało się, że leczenie wieloma lekami powoduje większe zmiany w składzie krwi niż leczenie jednym lekiem. Autorzy rekomendują stosowanie jednego leku, gdy to możliwe, i regularne badania krwi u wszystkich pacjentów.

Oryginalny abstract (angielski)

BackgroundThis study compared the effects of anti-seizure medication (ASM) monotherapy and polytherapy on hematological parameters in patients with epilepsy (PWE).ObjectiveTo compare hematological parameters and derived inflammatory indices in patients with epilepsy receiving ASM monotherapy versus polytherapy and determine independent predictors and discriminatory performance of these parameters.MethodsA hospital-based cross-sectional study was conducted between January and June 2024 at the Neurology Clinic of Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria. Two hundred adult PWE were enrolled and classified into monotherapy or polytherapy groups. Sociodemographic and clinical data were collected. Venous blood samples were analyzed using the Sysmex XN-1000 hematology analyzer. Statistical analyses included independent t-tests, chi-square tests, logistic regression, and receiver operating characteristic (ROC) analysis (p < 0.05).ResultsMales predominated in the monotherapy group (58.8%), while females predominated in the polytherapy group (84.1%; p < 0.001). Monotherapy showed significantly higher neutrophils, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, and neutrophil-lymphocyte ratio, but lower mean platelet volume. Neutrophils, hemoglobin, MCV, MCHC, and MPV independently predicted treatment pattern. ROC analysis showed moderate discrimination for MPV, while others performed poorly.ConclusionASM polytherapy is associated with greater hematological alterations. Monotherapy should be prioritized when feasible, with routine hematological monitoring recommended.

Metadane publikacji

Journal
Int J Risk Saf Med
Data publikacji
20.04.2026
PMID
42003518
DOI
10.1177/09246479261444923
Autorzy
Luqman O, Olabisi O, Adeola K, Ibironke O, Oluwatosin O, Joshua A, Olajumoke M, Oluwatosin O, Opeoluwa A, Precious A
Słowa kluczowe
clinical pharmacology, endocrine and metabolic disorders, internal medicine, neurology, pharmacology
Źródło
PubMed